NCT00791232View on ClinicalTrials.gov

A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

March 31, 2003

Study Completion Date

June 30, 2003

Conditions
Schizophrenia
Interventions
DRUG

extended-release (ER) OROS paliperidone

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00791232 - A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter